In the stock markets, Tesla has reportedly experienced a 1% rise in share prices. The data shows that the rise was experienced for the electric car manufacturing company in the premarket trading. The electric car manufacturing company has revealed that in the month of September, it has successfully sold a large number of vehicles. The electric-car company has announced that in the month of September, more than 56,000 vehicles have been sold. Tesla has announced that it successfully achieved these many sales in the month of September only in China.
It was two years back when Tesla had announced that it had achieved such a large volume of electric car manufactures. Since 2019, it is for the first time that Tesla has managed to achieve these many sales. The company has been making a gradual comeback from the recent upsets it had faced in terms of share prices. The company was down throughout the first half of 2021 due to many scrutinies it had to face from the Chinese and US regulators. The company had also faced several issues pertaining to its software and cruise control features. Now the company is making changes to the way it operates, in order to regain its old stock reputation.
Square is the next company on the list that has experienced a 1.6% increase in share prices after it had its stock status updated. The increase in the company’s stock prices was observed following the stock status update made by analysts from Atlantic Equities. The analysts from Atlantic Equities have updated the stock status of Square from “neutral” to “overweight”. The analysts have upgraded the status of the company due to the rise in the company’s growth and a significant rise in its valuation. According to the analysts, the company has been recording a significant rise in the growth of the prospects. The company has also made changes to the business model that seem productive for the company’s business model.
Moderna is constantly finding itself in the news because a month back, it announced successful results from its oral medicine for COVID-19. Just recently, the company has experienced another 1% rise in the share prices in the premarket trading. This is due to the possible outcome from the panel meeting for the Food and Drug Administration that is to take place on Thursday, October 21, 2021. The approval would be for the oral COVID-19 vaccine that is pending approval by the administrators. The company has already publicly shared and published the prospects it has arranged for the approval of the oral medicine. Following the approval, it is expected that the company is going to record a further increase in its share prices.